HUGH H. HUSSEY, M.D.; JOHN D. ARCHER, M.D.
To the editor: The recent article, "Propranolol," by Dr. Howard F. Morrelli (1) discusses defects in the manufacturer's package brochure for that drug in the context of its approval by the Food and Drug Administration (FDA). Although we could argue with scattered implications in the text, we acknowledge that, overall, it was a masterful dissection of the obsolete quality of the brochure. Nevertheless, a passage in the article's abstract is so disturbing that we feel compelled to comment—notwithstanding some discomfort, as editors of one medical journal in criticizing the content of another journal.
Dr. Morrelli cites the uses of propranolol
Learn more about subscription options.
Register Now for a free account.
HUSSEY HH, ARCHER JD. Propranolol and Labeling. Ann Intern Med. 1973;79:608–609. doi: 10.7326/0003-4819-79-4-608
Download citation file:
Published: Ann Intern Med. 1973;79(4):608-609.
Cardiology, Coronary Risk Factors, Hypertension, Infectious Disease, Nephrology.
Results provided by:
Copyright © 2017 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only